Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?
Authors
Keywords
Antisense oligonucleotide, induced pluripotent stem cell, continual reassessment model, futility design, selection design, historical placebo
Journal
Neurotherapeutics
Volume 12, Issue 2, Pages 376-383
Publisher
Springer Nature
Online
2015-02-20
DOI
10.1007/s13311-015-0341-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis
- (2014) R. Tortelli et al. EUROPEAN JOURNAL OF NEUROLOGY
- The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients
- (2014) Angelina Cistaro et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis
- (2014) Alon Abraham et al. JOURNAL OF NEUROLOGY
- Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis
- (2014) M. Pagani et al. NEUROLOGY
- Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS
- (2014) Zhaoming Su et al. NEURON
- Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms
- (2014) Leslie I. Grad et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intrinsic Membrane Hyperexcitability of Amyotrophic Lateral Sclerosis Patient-Derived Motor Neurons
- (2014) Brian J. Wainger et al. Cell Reports
- Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS)
- (2014) Sabrina Paganoni et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Predicting success: Optimizing phase II ALS trials for the transition to phase III
- (2014) James D. Berry et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
- (2013) Erica D. Koval et al. HUMAN MOLECULAR GENETICS
- An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
- (2013) Timothy M Miller et al. LANCET NEUROLOGY
- Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS
- (2013) Peter E.A. Ash et al. NEURON
- Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
- (2013) Johanna Gaiottino et al. PLoS One
- Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration
- (2013) C. Lagier-Tourenne et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS
- (2013) K. Mori et al. SCIENCE
- A Bayesian decision-theoretic sequential response-adaptive randomization design
- (2013) Fei Jiang et al. STATISTICS IN MEDICINE
- Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation
- (2013) C Parisi et al. Cell Death & Disease
- The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials
- (2013) James D. Berry et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72
- (2013) David MA Mann et al. Acta Neuropathologica Communications
- Electrical impedance myography as a biomarker to assess ALS progression
- (2012) Seward B. Rutkove et al. Amyotrophic Lateral Sclerosis
- Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival
- (2012) Jenny S. Henkel et al. EMBO Molecular Medicine
- Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression
- (2012) R. Tortelli et al. EUROPEAN JOURNAL OF NEUROLOGY
- Relationships between Disease Progression and Serum Levels of Lipid, Urate, Creatinine and Ferritin in Japanese Patients with Amyotrophic Lateral Sclerosis: A Cross-Sectional Study
- (2012) Ken Ikeda et al. INTERNAL MEDICINE
- Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS
- (2012) Oleg Butovsky et al. JOURNAL OF CLINICAL INVESTIGATION
- Uric acid levels predict survival in men with amyotrophic lateral sclerosis
- (2012) Sabrina Paganoni et al. JOURNAL OF NEUROLOGY
- Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis
- (2012) K. B. Boylan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms
- (2012) Weihua Zhao et al. NEUROBIOLOGY OF DISEASE
- SOD1 in Cerebral Spinal Fluid as a Pharmacodynamic Marker for Antisense Oligonucleotide Therapy
- (2012) Leah Winer et al. JAMA Neurology
- Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS
- (2011) Jeban Ganesalingam et al. JOURNAL OF NEUROCHEMISTRY
- Phase I Trials
- (2011) Matthew Macaluso et al. Journal of Psychiatric Practice
- Phase I Trials
- (2011) Matthew Macaluso et al. Journal of Psychiatric Practice
- Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials
- (2011) Patricia L. Andres et al. MUSCLE & NERVE
- The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
- (2011) Merit Cudkowicz et al. NATURE MEDICINE
- Multipoint incremental motor unit number estimation as an outcome measure in ALS
- (2011) J. M. Shefner et al. NEUROLOGY
- Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: Examining a more efficient trial design
- (2011) R. G. Miller et al. NEUROLOGY
- Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis
- (2011) Petra Steinacker et al. PLoS One
- Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells
- (2011) Christian Münch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Present and the Future of Neuroimaging in Amyotrophic Lateral Sclerosis
- (2010) F. Agosta et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- The culture of faith and hope
- (2010) Daniel P. Sulmasy et al. CANCER
- Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
- (2010) S. P. Ivy et al. CLINICAL CANCER RESEARCH
- An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis
- (2010) Stefano Zoccolella et al. JOURNAL OF NEUROLOGY
- Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
- (2010) Swati P Aggarwal et al. LANCET NEUROLOGY
- Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III
- (2009) Petra Kaufmann et al. ANNALS OF NEUROLOGY
- “Classical 3 + 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents
- (2009) Nicolas Penel et al. INVESTIGATIONAL NEW DRUGS
- Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker
- (2009) Kevin Boylan et al. JOURNAL OF NEUROCHEMISTRY
- CSF neurofilament protein analysis in the differential diagnosis of ALS
- (2009) Thierry S. Reijn et al. JOURNAL OF NEUROLOGY
- Low uric acid levels in serum of patients with ALS: Further evidence for oxidative stress?
- (2009) D. Keizman et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Applying proteomics to the diagnosis and treatment of ALS and related diseases
- (2009) Robert Bowser et al. MUSCLE & NERVE
- Electrical impedance myography: Background, current state, and future directions
- (2009) Seward B. Rutkove MUSCLE & NERVE
- A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS
- (2008) Paul H. Gordon et al. Amyotrophic Lateral Sclerosis
- Gene-Targeted Therapies for the Central Nervous System
- (2008) Timothy M. Miller et al. ARCHIVES OF NEUROLOGY
- A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
- (2008) Alexia Iasonos et al. Clinical Trials
- Biochemical Markers in CSF of ALS Patients
- (2008) Sigurd Sussmuth et al. CURRENT MEDICINAL CHEMISTRY
- Biomarkers in amyotrophic lateral sclerosis
- (2008) Martin R Turner et al. LANCET NEUROLOGY
- Systemic AAV6 Delivery Mediating RNA Interference Against SOD1: Neuromuscular Transduction Does Not Alter Disease Progression in fALS Mice
- (2008) Chris Towne et al. MOLECULAR THERAPY
- Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons
- (2008) J. T. Dimos et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started